TBRG · TruBridge, Inc. · Stock research

Current Thesis

The file that closed on 2026-07-09 has since been closed administratively as well. TruBridge shareholders received $26.25 per share in cash at the merger effective time; the company filed Form 25 with the SEC on 2026-07-09 to remove the common stock from the Nasdaq Global Select Market, and Form 15-12G on 2026-07-24, terminating Section 12(g) registration and suspending reporting obligations. TruBridge is a wholly owned subsidiary of Inventurus Knowledge Solutions (NSE: IKS). There is no US-listed equity to price, no filing stream, and no forward series to mark. What has changed since the last note is on the acquirer's side: IKS reported Q1 FY27 on 2026-08-06 and gave the first post-close commentary on what it bought.

Bullish and bearish views on TruBridge, Inc.

The model's bull view on TruBridge, Inc. (TBRG), in brief: The cash was paid at the signed number. $26.25/share, the exact consideration in the 2026-04-23 merger agreement — no collar, no stock leg, no earnout. No dissent to litigate. No holder exercised appraisal rights, despite a 2026-05-10 commentary piece arguing the fixed-cash… The bear view: Nothing remains to own. Registration terminated 2026-07-24. Any vendor still quoting TBRG is serving a stale symbol table. The successor is out of reach for a US-brokerage book. TruBridge economics now sit inside an NSE-listed Indian mid-cap, INR-denominated, on a different… Both cases follow in full.

Bull Case

• The cash was paid at the signed number. $26.25/share, the exact consideration in the 2026-04-23 merger agreement — no collar, no stock leg, no earnout.
• No dissent to litigate. No holder exercised appraisal rights, despite a 2026-05-10 commentary piece arguing the fixed-cash terms undervalued the equity and forced a tax event. For a sub-$600M take-private that is an unusually clean exit path.
• The financing closed and was then termed out. Press coverage dated 2026-08-03 reports IKS finalising a syndication of the acquisition funding behind the ~$557M purchase, following the up-to-$670M commitment from Citigroup, Deutsche Bank, JPMorgan and Citibank. Any residual scenario in which funding failure unwound the transaction is gone.
• The acquirer has put a number on the asset. On the 2026-08-06 Q1 FY27 release, IKS reported consolidated operating revenue of ₹893.63 crore, +21% YoY (12% constant currency) and PAT of ₹194 crore vs ₹152 crore a year earlier, with EBITDA margin 33% reported / 35% adjusted for one-time TruBridge acquisition costs, and stated it inherited roughly $68M of annualised EBITDA with TruBridge. Note that the quarter ended 2026-06-30, before the 2026-07-09 close — the revenue line does not yet include TruBridge; the transaction costs do. That is an inference from the reporting calendar, not a company statement.

Bear Case

• Nothing remains to own. Registration terminated 2026-07-24. Any vendor still quoting TBRG is serving a stale symbol table.
• The successor is out of reach for a US-brokerage book. TruBridge economics now sit inside an NSE-listed Indian mid-cap, INR-denominated, on a different disclosure regime and reporting calendar — a different risk object from the one this ticker described.
• The whole re-rate happened inside one halt. From the ~$16.24 pre-rumour standalone close (2026-04-02) to the cash cap in a single session: halted 9:21:59 a.m. ET on 2026-04-23, resumed 10:00 a.m. ET. No accumulation, no retest, no leg.
• Post-signing the payoff shape was ~$0.20 to the cap against ~$10 to the pre-rumour level — the structural reason the name never behaved like momentum after 2026-04-23.
• Coverage is gone. Cantor Fitzgerald suspended its Neutral rating on 2026-07-10, the routine termination after a completed take-private. No estimates, no targets, no updates.

Setup & Price Structure

• The narrative is dead. Dated by 2026-07-09 (effective time, trading ceased before the open, Form 25 filed) and 2026-07-24 (Form 15-12G). Not maturing, not saturated — terminated.
• Last completed adjusted daily close: $26.24 on 2026-07-08, one cent under the fixed $26.25 cash price. The 52-week high in the same series is $26.25.
• Screener fields are frozen artifacts. RSI(14) 75.0, three-month return +49.8%, 0.0% below the 52-week high — all computed off bars that stop on 2026-07-08 against a price pinned to a merger number. A momentum ranker reads that as strength; it is the arithmetic of a tape that ended.
• Crowding and positioning evidence is absent by construction, and that absence is the observable: no public float (the survivor is wholly owned), no post-2026-07-09 short-interest print, no options chain, no scheduled earnings date, no sell-side estimates after the 2026-07-10 coverage suspension. There is no bid to be thin or thick.

Catalyst Calendar (next 30 days)

• 2026-08-15 → 2026-09-14: nothing dated. No earnings, no SEC filings (reporting obligations suspended on the 2026-07-24 Form 15-12G), no exchange or index events for this symbol.
• ~2026-11-14 (est.) — IKS (NSE: IKS) Q2 FY27 results. Outside the window. This is the first reporting period that includes TruBridge post-close; the date is estimated from the quarterly cadence that produced the 2026-08-06 Q1 release, not company-confirmed.

What Would Change Our Mind

The structure that would have to reappear is a listed security. Concretely: a Form 8-A or exchange listing notice for a TruBridge successor, an IKS carve-out or re-IPO of the US assets filed on an S-1, or a US depositary line on Inventurus Knowledge Solutions — none of which exists today. Absent that, the gradeable form of this read is that a daily close below $26.25 cannot print: the adjusted series ends 2026-07-08 at $26.24 and the equity converted to cash the following morning. A second condition worth watching is symbol reuse — Nasdaq can reassign a retired ticker, and a TBRG quote appearing without a matching listing filing should be treated as a different issuer or a data artifact, not a resumption. If IKS's Q2 FY27 report shows TruBridge revenue materially below the ~$68M annualised EBITDA framing given on 2026-08-06, that is information about the acquirer's equity, not about a security anyone here can price.

Correlation Notes

• No US-listed correlate remains. The residual exposure is an INR-denominated NSE mid-cap; USD/INR and Indian mid-cap flows are now inputs on a risk object a US reader was not previously carrying.
• That is a live datapoint for other small-cap US health-IT and revenue-cycle names being modelled as cross-border takeout candidates.
• Data-asset framing. On the 2026-08-06 call IKS described building proprietary small language models on TruBridge's 5 million-plus patient dataset. Whether that framing survives contact with a P&L is an IKS question; it is the kind of claim that tends to be applied by analysts to other holders of large clinical datasets.
• Sleeve accounting. For anyone tracking special-situation carry versus momentum, this name's entire return was delivered in one halted gap on 2026-04-23 and then converted to cash — it correlates with deal-completion risk, and with nothing on a chart.